论文部分内容阅读
目的:探讨芎芍胶囊治疗冠心病介入术后再狭窄的临床疗效。方法:将平顶山市第二人民医院收治的93例行介入治疗的冠心病患者按照随机对照原则分为观察组(49例)与对照组(44例),对照组患者术后给予常规西医治疗,观察组患者在此基础上给予芎芍胶囊治疗,术后对患者进行随访,通过复查冠状动脉造影,观察两组患者术后再狭窄发生情况。结果:观察组患者介入治疗后再狭窄发生率为16.3%,低于对照组患者的36.4%,组间差异有统计学意义(P<0.05);观察组患者介入治疗后的最小管腔直径小于对照组患者,狭窄程度低于对照组患者,组间差异有统计学意义(P<0.05)。结论:芎芍胶囊在防治冠心病介入术后再狭窄方面具有较好的效果。
Objective: To investigate the clinical efficacy of Xiongshao capsule in the treatment of restenosis after coronary intervention. Methods: Ninety-three patients with coronary heart disease undergoing interventional therapy in Second People’s Hospital of Pingdingshan City were divided into observation group (n = 49) and control group (n = 44) according to the principle of randomized control. Patients in control group were given routine Western medical treatment after operation, Patients in the observation group were treated with Xiongshao capsules on this basis. Patients were followed up after surgery. Coronary angiography was performed to observe the postoperative restenosis in both groups. Results: The incidence of restenosis in the observation group was 16.3% after interventional treatment, which was lower than that in the control group (36.4%), the difference was statistically significant (P <0.05). The minimum lumen diameter after interventional treatment in the observation group was less than In the control group, the degree of stenosis was lower than that in the control group. There was significant difference between the two groups (P <0.05). Conclusion: Xiongshao capsules in the prevention and treatment of coronary artery stenosis after restenosis has good results.